InVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President, Clinical Operations, will present at the Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting on Saturday, May 13, 2017 at 2:40 PM ET at the Marriott Eaton Center in Toronto, Ontario. Ms. Neff will present an abstract titled “Interim Clinical Results from the Ongoing INSPIRE Pivotal Study to Assess the Safety and Probable Benefit of the Investigational Neuro-Spinal Scaffold for Treatment of Acute Thoracic AIS A Spinal Cord Injury.”

Mark Perrin, Chairman and CEO, said, “The Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting will be a great opportunity for us to continue to engage with the Canadian spinal cord injury research and care network, and we look forward to providing an update on the INSPIRE clinical results.”

For more information on the INSPIRE study, please visit the company’s ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles